Literature DB >> 16652150

Identification of expressed genes characterizing long-term survival in malignant glioma patients.

R Yamanaka1, T Arao, N Yajima, N Tsuchiya, J Homma, R Tanaka, M Sano, A Oide, M Sekijima, K Nishio.   

Abstract

Better understanding of the underlying biology of malignant gliomas is critical for the development of early detection strategies and new therapeutics. This study aimed to define genes associated with survival. We investigated whether genes coupled with a class prediction model could be used to define subgroups of high-grade gliomas in a more objective manner than standard pathology. RNAs from 29 malignant gliomas were analysed using Agilent microarrays. We identified 21 genes whose expression was most strongly and consistently related to patient survival based on univariate proportional hazards models. In six out of 10 genes, changes in gene expression were validated by quantitative real-time PCR. After adjusting for clinical covariates based on a multivariate analysis, we finally obtained a statistical significance level for DDR1 (discoidin domain receptor family, member 1), DYRK3 (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3) and KSP37 (Ksp37 protein). In independent samples, it was confirmed that DDR1 protein expression was also correlated to the prognosis of glioma patients detected by immunohistochemical staining. Furthermore, we analysed the efficacy of the short interfering RNA (siRNA)-mediated inhibition of DDR1 mRNA synthesis in glioma cell lines. Cell proliferation and invasion were significantly suppressed by siRNA against DDR1. Thus, DDR1 can be a novel molecular target of therapy as well as an important predictive marker for survival in patients with glioma. Our method was effective at classifying high-grade gliomas objectively, and provided a more accurate predictor of prognosis than histological grading.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652150     DOI: 10.1038/sj.onc.1209585

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

Review 1.  Discoidin domain receptor tyrosine kinases: new players in cancer progression.

Authors:  Rajeshwari R Valiathan; Marta Marco; Birgit Leitinger; Celina G Kleer; Rafael Fridman
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

2.  The changing face of brain tumours. Preface.

Authors:  A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 3.  Discoidin domain receptors: a proteomic portrait.

Authors:  Leo K Iwai; Maciej T Luczynski; Paul H Huang
Journal:  Cell Mol Life Sci       Date:  2014-04-05       Impact factor: 9.261

Review 4.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

5.  Discoidin domain receptor 1: New star in cancer-targeted therapy and its complex role in breast carcinoma.

Authors:  Hui Jing; Jingyuan Song; Junnian Zheng
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

6.  Gene expression in oligodendroglial tumors.

Authors:  Elisabeth J Shaw; Brian Haylock; David Husband; Daniel du Plessis; D Ross Sibson; Peter C Warnke; Carol Walker
Journal:  Cell Oncol (Dordr)       Date:  2011-05-31       Impact factor: 6.730

7.  Regulation of collagen fibrillogenesis by cell-surface expression of kinase dead DDR2.

Authors:  Angela R Blissett; Derek Garbellini; Edward P Calomeni; Cosmin Mihai; Terry S Elton; Gunjan Agarwal
Journal:  J Mol Biol       Date:  2008-10-30       Impact factor: 5.469

Review 8.  FGF binding proteins (FGFBPs): Modulators of FGF signaling in the developing, adult, and stressed nervous system.

Authors:  Thomas Taetzsch; Vanessa L Brayman; Gregorio Valdez
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-06-12       Impact factor: 5.187

9.  Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy.

Authors:  Yoko Kita; Satomi Hashimoto; Toshihiro Nakajima; Hitoshi Nakatani; Shiho Nishimatsu; Yasuko Nishida; Noriko Kanamaru; Yasuhumi Kaneda; Yasushi Takamori; David McMurray; Esterlina V Tan; Marjorie L Cang; Paul Saunderson; E C Dela Cruz; Masaji Okada
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

Review 10.  The pathobiology of collagens in glioma.

Authors:  Leo S Payne; Paul H Huang
Journal:  Mol Cancer Res       Date:  2013-07-16       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.